Population | TCR index | mCRPC | Melanoma | ||
Correlation | P value | Correlation | P value | ||
CD8+count at baseline | Clonality at baseline | 0.71 | 0.003 | 0.81 | <0.001 |
CD8+count at baseline | Relative clonality | −0.59 | 0.022 | −0.82 | <0.001 |
CD8+count at baseline | Proportion of increase clones | 0.13 | 0.648 | 0.58 | 0.029 |
CD8+count at baseline | Proportion of decrease clones | −0.57 | 0.026 | −0.54 | 0.045 |
CD8+ratio | Relative clonality | 0.50 | 0.170 | 0.55 | 0.041 |
CD8+ratio | Proportion of increase clones | −0.22 | 0.576 | −0.69 | 0.007 |
CD8+ratio | Proportion of decrease clones | 0.23 | 0.546 | 0.61 | 0.020 |
CD4+count at baseline | Clonality at baseline | 0.34 | 0.216 | 0.28 | 0.326 |
CD4+count at baseline | Relative clonality | −0.53 | 0.038 | −0.29 | 0.311 |
CD4+count at baseline | Proportion of increase clones | 0.37 | 0.173 | 0.34 | 0.233 |
CD4+count at baseline | Proportion of decrease clones | −0.38 | 0.160 | −0.34 | 0.220 |
CD4+ratio | Relative clonality | 0.13 | 0.732 | 0.24 | 0.418 |
CD4+ratio | Proportion of increase clones | 0.07 | 0.864 | −0.28 | 0.326 |
CD4+ratio | Proportion of decrease clones | 0.63 | 0.067 | 0.24 | 0.409 |
CD8+ and CD4+ count ratios were calculated as the count in the corresponding population at on-treatment divided by that at baseline.
p<0.05 denoted in bold.
mCRPC, metastatic castration resistant prostate cancer; TCR, T-cell receptors.